Advertisement

Cardiomyopathy

Chapter
  • 737 Downloads
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Cardiomyopathies are classified as follows:
  • Hypertrophic cardiomyopathy.

  • Dilated cardiomyopathy.

  • Restrictive cardiomyopathy.

  • Arrhythmogenic right ventricular (RV) cardiomyopathy (RV dysplasia).

  • Unclassified cardiomyopathy: diseases that do not have features of 1 to 4 and include fibroelastosis and mitochondrial disease.

  • Specific cardiomyopathies (specific heart muscle diseases formerly termed secondary cardiomyopathy).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. 1.
    Ackerman MJ, McKenna WJ, Thierfelder L, et al. mutations in the genes for cardiac troponins T an alpha tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995;332:1058–1064.CrossRefGoogle Scholar
  2. 2.
    Andersson B, Hamm C, Persson S, et al. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. J Am Coll Cardiol 1994;23:1397.PubMedGoogle Scholar
  3. 3.
    AVID: The Antiarrhythmic Versus Implantable Defibrillators Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576–1583.CrossRefGoogle Scholar
  4. 4.
    Boriani G, Maron BJ, Shen Win-Kuang, et al. Prevention of sudden death in hypertrophic cardiomyopathy: but which defibrillator for which patient? Circulation 2004;110:e438–e442.PubMedCrossRefGoogle Scholar
  5. 5.
    Bowles NE, Richardson PJ, Olsen EGJ, et al. Detection of Coxsackie-B virus specific RNA sequence in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1986;1:1120.PubMedCrossRefGoogle Scholar
  6. 6.
    Braunwald E, Seidman CE, Sigwart U. Contemporary evaluation and management of hypertrophic cardiomyopathy. Circulation 2002;106:1312–1316.PubMedCrossRefGoogle Scholar
  7. 7.
    CAPRICORN Investigators. The effect of carvedilol on outcome after myocardial infarcion in patients with left ventricular dysfunciton. The CAPRICORN randomized trial. Lancet 2001:357:1385–1390.CrossRefGoogle Scholar
  8. 8.
    Cice G, Ferrara L, Benedetto AD, et al. dilated cardiomyopathy in dialysis patients beneficial effects of carvedilol double-blind, placebo-controlled trial. J Am Coll Cardiol 2001;57:47–111.Google Scholar
  9. 9.
    COPERNICUS: carvedilol prospective randomized cumulative survival study group effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658.Google Scholar
  10. 10.
    Corrado D, Nava A, Buja G, et al. Familial cardiomyopathy underlies syndrome of right bundle branch block, ST segment elevation and sudden death. J Am Coll Cardiol 1996;27:443.PubMedCrossRefGoogle Scholar
  11. 11.
    Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol 2003;42:1959–1963.PubMedCrossRefGoogle Scholar
  12. 12.
    Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994;331:1564.PubMedCrossRefGoogle Scholar
  13. 13.
    Deckers JW, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J Am Coll Cardiol 1992;9:43.CrossRefGoogle Scholar
  14. 14.
    Elliott PM, Blanes G, Mahon JR, et al. A relation between the severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy bands at 2001;357:420–424.Google Scholar
  15. 15.
    EPHESUS: Pitt B, Remme W, Zannad F, et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarcion. N Engl J Med 2003;348:1309–1321.PubMedCrossRefGoogle Scholar
  16. 16.
    Eriksson MJ, Sonnenberg B, Woo A, et al. long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:638–645.PubMedCrossRefGoogle Scholar
  17. 17.
    Fananapazir L, O’Connor RO, Tripodi D, et al. Impact of dual chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation 1992;85:2149.PubMedGoogle Scholar
  18. 18.
    Goodwin JF, Olsen EGJ (eds). Cardiomyopathies: realizations and expectations. Berlin: Springer Verlag, 1993.Google Scholar
  19. 19.
    Grody WW, Cheng L, Lewis W. Infection of the heart by the human immunodeficiency virus. J Am Coll Cardiol 1990;66:203.Google Scholar
  20. 20.
    Hejtmancik JF, Brink PA, Towbin J, et al. Localization of gene for familial hypertrophic cardiomyopathy to chromosome 14ql in a diverse US population. Circulation 1991;83:1592.PubMedGoogle Scholar
  21. 21.
    Hess OM, Sigwart U. New treatment strategies for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2004;44:2054–2055.PubMedCrossRefGoogle Scholar
  22. 22.
    Kappenberger L. Pacing for obstructive hypertrophic cardiomyopathy. Br Heart J 1995;73:107.PubMedCrossRefGoogle Scholar
  23. 23.
    Kasper EK, Agema WRP, Hutchings GM, et al. The causes of dilated cardiomyopathy: a clinicopatholigic review of 673 consecutive patients. J Am Coll Cardiol 1994;23:586.PubMedGoogle Scholar
  24. 24.
    Leung WH, Lau CP, Wong CK, et al. Improvement in exercise performance and hemodynamic by labetalol in patients with idiopathic dilated cardiomyopathy. Am Heart J 1990;119:884.PubMedCrossRefGoogle Scholar
  25. 25.
    Lowes BD, Gilbert EM, Abraham WT, et al. myocardial gene expression in dilated cardiomyopathy treated with beta blocking agents. N Engl J Med 2002;346:1357–1365.PubMedCrossRefGoogle Scholar
  26. 26.
    Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308–1320.PubMedCrossRefGoogle Scholar
  27. 27.
    Maron BJ, Estes NA 3rd, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation. 2003;107:2872–2875.PubMedCrossRefGoogle Scholar
  28. 28.
    Maron B J, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CAR-DIA Study. Circulation 1995;92:785.PubMedGoogle Scholar
  29. 29.
    Maron BJ, Dearani JA, Ommen SR, et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:2044–2053.PubMedCrossRefGoogle Scholar
  30. 30.
    Maron B J, Seidman JG, Seidman CE. Proposal for contempory screenings strategies in families with hyper-trophic cardiomyopathy. J Am Coll Cardio. 2004;44:2125–2132.CrossRefGoogle Scholar
  31. 31.
    McKenna WJ, Mogensen J, Elliott PM. Role of genotype in risk factor assessment for sudden death in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:249–251.CrossRefGoogle Scholar
  32. 32.
    Nishimura RA, Hayes DL, Ilstrup DM, et al. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler Echocardiographic and Catheterization Hemodynamic Study. J Am Coll Cardiol 1996;27:421.PubMedCrossRefGoogle Scholar
  33. 33.
    Nishimura RA, Holmes DR. Hypertrophic obstructive cardiomyopathy. N Eng J Med 2004;350:1320–1327.CrossRefGoogle Scholar
  34. 34.
    Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349.PubMedCrossRefGoogle Scholar
  35. 35.
    Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 2002;106:2194–2187.PubMedCrossRefGoogle Scholar
  36. 36.
    Roberts R, Sigwart U. New concepts in hypertrophic cardiomyopathies, part II. Circulation 2001;104:2249–2252.PubMedCrossRefGoogle Scholar
  37. 37.
    Ryan MP, Cleland JFG, French J A, et al. The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. Am J Cardiol 1995;76:689.PubMedCrossRefGoogle Scholar
  38. 38.
    Shamim W, Yousufuddin M, Wang D, et al. Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med 2002;347:1326–1333.PubMedCrossRefGoogle Scholar
  39. 39.
    Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211.PubMedCrossRefGoogle Scholar
  40. 40.
    Spirito P, Bellone P, Harris KM, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778–1785.PubMedCrossRefGoogle Scholar
  41. 41.
    Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995;332:1058.PubMedCrossRefGoogle Scholar
  42. 42.
    Webb JG, Sasson Z, Rakowski H, et al. Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates. J Am Coll Cardiol 1990;15:83.PubMedGoogle Scholar
  43. 43.
    Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 1995;92:1680.PubMedGoogle Scholar
  44. 44.
    Williams RG, Chen AY. Identifying athletes at risk for sudden death. J Am Coll Cardiol 2003;42:1964–1966.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Personalised recommendations